TP53 and hepatocellular carcinoma: Prospective next-generation sequencing studies by Harding et al. provided predictive and prognostic insights for HCC patients receiving systemic therapy, revealing frequent alterations in TP53 (33%) and the Wnt/β-catenin pathway (45%), which represent mutually exclusive molecular subsets (Harding et al., 2019).